AIM: To evaluate the baseline visual and optical coherence tomography (OCT) factors on outcomes after intravitreal bevacizumab treatment of subfoveal neovascular age-related macular degeneration (AMD). METHODS: A retrospective analysis of 73 eyes treated with intravitreal bevacizumab for subfoveal neovascular AMD was performed. Change in best corrected Snellen visual acuity (BCVA) and central retinal thickness (CRT) on OCT were the primary outcomes. Automated and manual measurements were made for all OCT characteristics. RESULTS: Seventy-three (100%) and 58 (79.5%) eyes were followed for 3 and 6 months, respectively. The mean BCVA improved from 20/177 to 20/160 (p = 0.03) at 3 months and to 20/143 (p = 0.04) at 6 months. The mean CRT decreased 93 microm (p<0.0001) and 105 microm (p<0.0001) at 3 and 6 months, respectively. Baseline BCVA worse than 20/100 was associated with greater visual improvement (p< or =0.04). Eyes with baseline CRT greater than 400 microm experienced a greater mean CRT reduction (p<0.05). Treatment-naïve patients had a greater mean CRT reduction than those previously treated with any modality (p<0.05) CONCLUSIONS: Baseline BCVA and CRT positively influence mean visual and CRT improvement, respectively, after intravitreal bevacizumab in wet AMD. Any prior treatment predicted less CRT reduction.
AIM: To evaluate the baseline visual and optical coherence tomography (OCT) factors on outcomes after intravitreal bevacizumab treatment of subfoveal neovascular age-related macular degeneration (AMD). METHODS: A retrospective analysis of 73 eyes treated with intravitreal bevacizumab for subfoveal neovascular AMD was performed. Change in best corrected Snellen visual acuity (BCVA) and central retinal thickness (CRT) on OCT were the primary outcomes. Automated and manual measurements were made for all OCT characteristics. RESULTS: Seventy-three (100%) and 58 (79.5%) eyes were followed for 3 and 6 months, respectively. The mean BCVA improved from 20/177 to 20/160 (p = 0.03) at 3 months and to 20/143 (p = 0.04) at 6 months. The mean CRT decreased 93 microm (p<0.0001) and 105 microm (p<0.0001) at 3 and 6 months, respectively. Baseline BCVA worse than 20/100 was associated with greater visual improvement (p< or =0.04). Eyes with baseline CRT greater than 400 microm experienced a greater mean CRT reduction (p<0.05). Treatment-naïve patients had a greater mean CRT reduction than those previously treated with any modality (p<0.05) CONCLUSIONS: Baseline BCVA and CRT positively influence mean visual and CRT improvement, respectively, after intravitreal bevacizumab in wet AMD. Any prior treatment predicted less CRT reduction.
Authors: Konrad R Koch; Philipp S Muether; Manuel M Hermann; Robert Hoerster; Bernd Kirchhof; Sascha Fauser Journal: Graefes Arch Clin Exp Ophthalmol Date: 2011-09-08 Impact factor: 3.117
Authors: Kai Xiong Cheong; Dilraj Singh Grewal; Kelvin Yi Chong Teo; Alfred Tau Liang Gan; Glenn Jay Jaffe; Gemmy Chui Ming Cheung Journal: Eye (Lond) Date: 2020-02-11 Impact factor: 3.775
Authors: Sarah Sabour-Pickett; James Loughman; John M Nolan; Jim Stack; Konrad Pesudovs; Katherine A Meagher; Stephen Beatty Journal: J Ophthalmol Date: 2013-02-21 Impact factor: 1.909
Authors: Miltiadis K Tsilimbaris; Maria I López-Gálvez; Roberto Gallego-Pinazo; Philippe Margaron; George N Lambrou Journal: J Ophthalmol Date: 2016-03-17 Impact factor: 1.909
Authors: Georges Azar; Benjamin Wolff; Flore De Bats; Jeremie Halfon; Mate Streho; Sarah Tick; Laurent Castelnovo; Guillaume Michel; Helene Masse; Vivien Vasseur; Marwan Sahyoun; Martine Mauget-Faÿsse Journal: Biomed Res Int Date: 2018-06-26 Impact factor: 3.411